Selank

Description

Selank is a synthetic heptapeptide developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. Its structure combines a modified tuftsin fragment (the body’s natural immunomodulatory peptide) with a Pro-Gly-Pro sequence that enhances metabolic stability. Approved in Russia as a prescription anxiolytic, Selank represents one of the few peptides with both clinical approval and extensive nootropic research data.

Research Profile

Selank modulates multiple neurotransmitter systems simultaneously — increasing BDNF (brain-derived neurotrophic factor) expression, modulating serotonin metabolism, and influencing the balance of IL-6 cytokine expression. EEG studies show increased alpha wave activity (associated with calm focus) without the sedation or cognitive impairment seen with benzodiazepine-class compounds. Research in the Journal of Psychopharmacology documented anxiolytic effects comparable to medazepam but without dependency or withdrawal profiles.

Key Research Areas

• Anxiolytic activity without sedation or dependence
• BDNF upregulation and neuroplasticity
• Memory consolidation and learning enhancement
• Serotonin metabolism modulation
• Immunomodulatory activity (tuftsin backbone)

Specifications

Sequence	Thr-Lys-Pro-Arg-Pro-Gly-Pro
Molecular Weight	751.87 g/mol
Purity	≥99% (HPLC verified)
Form	Lyophilized powder
Quantity	5mg per vial
Storage	-20°C pre-reconstitution

Related Research Peptides

Selank and Semax were developed by the same institute and are frequently studied together — Selank for anxiolytic/calming effects, Semax for stimulatory cognitive enhancement. See DSIP for sleep research and our nootropic peptides guide.

Research Dosage Protocols

Selank has Russian clinical approval as an anxiolytic and nootropic peptide, with approved intranasal delivery at 250–500mcg per dose (3 drops of a 0.15% solution). Research protocols use subcutaneous injection at 200–500mcg doses, or intranasal delivery mimicking the clinical route for CNS-focused studies. A 5mg vial reconstituted in 2mL bacteriostatic water yields 2,500mcg/mL. Intranasal Selank research dilutes the working solution to 1–2mg/mL for volume compatibility with nasal delivery. Experimental windows in published anxiety and cognitive studies run 10–30 days, with effects observed as early as day 1 in acute administration models.

Frequently Asked Questions

What does Russian clinical approval mean for Selank’s research credibility?

Selank was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences and received clinical approval in Russia for “anxiety disorders and neurasthenia” — a regulatory pathway that included controlled clinical trials. This isn’t simply preclinical animal data: Russian clinical trials involved human subjects with measured anxiety and cognitive outcomes. The approval basis includes anxiolytic efficacy comparable to benzodiazepines at clinical doses, without sedation or dependence. Western researchers don’t have easy access to the original Russian trial data, but the clinical approval status places Selank above purely preclinical research peptides in terms of human-context safety and efficacy data.

What is the difference between intranasal and subcutaneous Selank research?

Intranasal delivery is clinically relevant for CNS-targeted Selank research because the olfactory route allows partial direct CNS access — bypassing the blood-brain barrier to some extent via olfactory nerve transport. The approved clinical preparation is intranasal. Subcutaneous injection provides systemic distribution with CNS penetration dependent on blood-brain barrier permeability. For researchers studying peripheral immune effects (Selank has documented enkephalin peptidase inhibition and immune regulatory activity), subcutaneous delivery is appropriate. For anxiety, memory, and BDNF studies that need to mirror the clinical delivery route, intranasal delivery is the more validated approach.

How does Selank’s BDNF mechanism work?

Brain-derived neurotrophic factor (BDNF) is a neurotrophin critical for synaptic plasticity, learning, and neuronal survival. Selank research shows it upregulates BDNF expression in hippocampal tissue, which may underlie the cognitive enhancement effects observed in animal models. The proposed mechanism involves Selank’s interaction with enkephalin-degrading enzymes — Selank inhibits enzymes that break down met-enkephalin and leu-enkephalin, increasing endogenous opioid peptide levels. These opioid peptides can modulate BDNF expression. Selank also shows direct effects on GABA receptor function, contributing to anxiolytic effects independent of the BDNF pathway.

Does Selank cause sedation in research models?

No — this is one of Selank’s key differentiating features versus benzodiazepines and traditional anxiolytics. Russian clinical trials specifically noted that Selank produced anxiolytic effects without sedation, motor impairment, or cognitive blunting that characterize benzodiazepine action. Animal models using open-field tests and rotarod performance confirm no significant motor sedation at therapeutic anxiolytic doses. Selank’s lack of sedation is attributed to its mechanism (enkephalin system and GABA modulation with BDNF enhancement) versus the broad CNS depression of GABA-A potentiation by benzodiazepines. This makes Selank relevant for daytime anxiety research where sedation confounds are a problem.

How does Selank compare to Semax?

Both are Russian-approved heptapeptides with nootropic/neuroprotective profiles, but their mechanisms and effects differ. Semax is an ACTH analog focused on cognitive enhancement, neuroprotection, and BDNF elevation through neurotrophin pathways. Selank is a tuftsin analog emphasizing anxiolytic effects, immune modulation, and anti-stress activity. Semax is more activating (stimulant-like in some users); Selank is more calming without sedation. Some research protocols combine them for complementary anxiolysis plus cognitive enhancement, though combined studies are limited. Researchers choosing between them should consider whether the study question is primarily about cognition (Semax) or anxiety/stress response (Selank).

What is the tuftsin backbone of Selank, and why does it matter?

Tuftsin is a naturally occurring tetrapeptide (Thr-Lys-Pro-Arg) derived from IgG immunoglobulin. It’s an endogenous immune regulatory peptide produced in the spleen that stimulates phagocytic activity of neutrophils and macrophages. Selank is a synthetic heptapeptide analog: Thr-Lys-Pro-Arg-Pro-Gly-Pro — tuftsin’s four amino acids extended with a proline-glycine-proline sequence that stabilizes it against enzymatic degradation. The tuftsin backbone is why Selank has both immunomodulatory properties (NK cell activity, interferon levels) in addition to CNS effects. The dual immune and neurological activity profile is baked into its molecular heritage.

How long do effects last in Selank research, and is there tolerance development?

Acute anxiolytic effects in animal models are measurable within 15–30 minutes of administration and persist for 4–8 hours depending on delivery route and dose. Published studies show no significant tolerance development over 10–30 day research periods — repeated administration doesn’t require dose escalation to maintain efficacy, which distinguishes it from benzodiazepines that show clear tolerance and dependence characteristics. Russian clinical experience with longer use periods similarly doesn’t document tolerance or withdrawal phenomena. This absence of tolerance is consistent with Selank’s mechanism (enzyme inhibition and BDNF modulation) rather than direct receptor downregulation that drives benzodiazepine tolerance.

For research and laboratory use only. Not for human consumption. All peptides are sold strictly as research chemicals.